A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

PURPOSE: This phase I study was conducted to evaluate the safety, tolerability, pharmacological properties and biological activity of the combination of the lonafarnib, a farnesylproteintransferase (FTPase) inhibitor, with gemcitabine and cisplatin in patients with advanced solid malignancies. EXPER...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chow, Laura Q. M., Eckhardt, S. Gail, O’Bryant, Cindy L., Schultz, Mary Kay, Morrow, Mark, Grolnic, Stacy, Basche, Michele, Gore, Lia
Formato: Artigo
Idioma:Inglês
Publicado em: 2007
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2813768/
https://ncbi.nlm.nih.gov/pubmed/18058098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-007-0646-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados